Immune response to an allogeneic progressively growing solid tumor

Cancer Research
|June 1, 1976
PubMed

A C57BL/6 (B6) methylcholanthrene-induced solid tumor grows progressively in BALB/c mice. The BALB/c mice fail to develop in their spleens cytotoxic lymphocytes directed against the histocompatibility (H-) antigens of the tumor. A B6 skin graft is rejected normally by mice with the progressively growing B6 tumor and skin graft rejection has no influence on the growth of the tumor. Tissue culture-carried tumor cells work satisfactorily as target cells in a 51Cr release assay with effector lymphocytes immunized against B6 H-antigens, but the tumor cells will not work as an immunogen for H-antigens for an in vitro immunization. "Fresh" tumor cells removed from their in vivo environment and separated on a discontinuous bovine serum albumin gradient also work as target cells. The conclusion is drawn that the host cytotoxic lymphocyte response against the tumor, as defined by a short-term 51Cr release assay, suffers from both sensitization and effector stage defects that probably do not involve serum factors or suppressor cells.

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...